ArticleAdvances in therapy2026
Multi-Indication Budget Impact Analysis of Subcutaneous IgPro20 Pre-filled Syringes for the Treatment of Primary Immunodeficiency Syndromes, Secondary Immunodeficiencies, and Chronic Inflammatory Demyelinating Polyneuropathy in Italy.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrimary immunodeficiency (PID) and secondary immunodeficiency (SID) are chronic conditions associated with impaired immune function and increased susceptibility to infections. Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune neurological disorder characterized by progressive motor and sensory deficits due to immune-mediated demyelination of peripheral nerves. Patients with these diseases often require long-term immunoglobulin (IG) therapy, which can be costly and burdensome, particularly when administered intravenously in hospital settings. IgPro20 pre‑filled syringes (PFS) offer a simplified, subcutaneous IG alternative that may reduce treatment burden and improve cost‑efficiency. The aim of this study was to estimate the budget impact of introducing IgPro20 PFS into the Italian healthcare system for patients with PID, SID, and CIDP.
methodsA population-based budget impact model was developed in Microsoft Excel® from the perspective of the Italian National Health Service (Servizio Sanitario Nazionale). The model used a 3-year time horizon and incorporated drug acquisition, administration, and adverse event costs. Model comparators included intravenous and subcutaneous IG and IgPro20 vials. Population estimates and market shares were informed by Italian affiliates.
resultsThe introduction of IgPro20 PFS resulted in total cost savings of €31,524,488 for 4794 patients over 3 years. Savings were distributed across PID (€8,840,041), SID (€5,413,035), and CIDP (€17,271,412). Sensitivity analyses identified IgPro20 PFS and vial pricing as key drivers.
conclusionIgPro20 PFS are a cost-saving, patient-centric treatment option for PID, SID, and CIDP. These findings support their adoption in Italy's healthcare system and may inform policy and payer decisions at regional and national levels.
Indexed as
Identifiers
42804081What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.